gastroparesis and glp 1 drugs What Patients Should Know About GLP-1s Gastrointestinal effect and adverse effects

doi: 10.1016/j.cmet.2011.02.001

PMID 24112036

Recent clinical trials demonstrated that SGLT2 inhibitors and GLP-1RAs bring beneficial effects on the cardiorenal outcomes of T2D subjects who are at high risk for CVD

Zhang, L., Zhang, W

A synthetic version was created in the years after, but it took until 2005 for this GLP-1 agonist to become an FDA-approved treatment for type 2 diabetes

did not find any significant changes of renin, aldosterone, and urinary angiotensinogen after a single GLP-1 infusion in healthy men 28 and the same result was reported in patients with diabetes without kidney function impairment 32